Ignite Creation Date:
2024-05-05 @ 5:31 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00470678
Status:
COMPLETED
Last Update Posted:
2016-11-18
First Post:
2007-05-07
Brief Title:
EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization CNV Secondary to Age-related Macular Degeneration AMD
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
An Open-label Multicenter Study to Evaluate the Efficacy and Safety of Ranibizumab 05 mg in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Over 12 Months
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate efficacy and safety for monthly ranibizumab 05 mg intravitreal injections in Asian patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None